NEW YORK (GenomeWeb News) – Danaher today said that revenues in the fourth quarter rose nearly 6 percent year over year paced by its Life Sciences and Diagnostics segment.

For the three months ended Dec. 31, 2012, the company posted total revenues of $4.98 billion, up from $4.72 billion in the year-ago period, and beating the consensus Wall Street estimate of $4.81 billion.

Core revenues increased 3.5 percent year over year during the quarter, while acquisitions added 3 percent growth, and the impact of currency translation cut growth by 1 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.